RSS-Feed abonnieren
DOI: 10.1055/s-0039-1697591
Gastrointestinal and Hepatobiliary Disease in Cystic Fibrosis
Publikationsverlauf
Publikationsdatum:
28. Oktober 2019 (online)
![](https://www.thieme-connect.de/media/srccm/201906/lookinside/thumbnails/10-1055-s-0039-1697591_01485-1.jpg)
Abstract
Cystic fibrosis (CF) is a multiorgan disease, and gastrointestinal (GI) manifestations can contribute to significant morbidity and mortality for individuals with CF. Up to 85% of patients with CF experience GI symptoms, thus addressing the GI aspects of this disease is paramount. With the advent of highly effective CF transmembrane conductance regulator modulators that are increasingly available, many individuals with CF now have significantly improved life expectancy. With these advances, GI manifestations that can be a detriment to quality of life such as gastroesophageal reflux disease, dysbiosis, and chronic abdominal pain have become a priority for patients and caregivers. In addition, as individuals have increased longevity, it has become essential for care providers to be aware of topics such as hepatobiliary disease and colorectal cancer screening. An understanding of the wide scope of GI manifestations in CF can enable providers to optimize the overall health and well-being of their patients. In this review, we aim to provide an up-to-date overview of key aspects of GI and hepatic disease in CF.
Keywords
meconium ileus - gastroesophageal reflux disease - distal intestinal obstruction syndrome - dysbiosis - hepatobiliary - pancreatic function* Both the author contributed equally to the article.
-
References
- 1 Brodzicki J, Trawińska-Bartnicka M, Korzon M. Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. Med Sci Monit 2002; 8 (07) CR529-CR537
- 2 Pauwels A, Blondeau K, Mertens V. , et al. Gastric emptying and different types of reflux in adult patients with cystic fibrosis. Aliment Pharmacol Ther 2011; 34 (07) 799-807
- 3 Robinson NB, DiMango E. Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease. Ann Am Thorac Soc 2014; 11 (06) 964-968
- 4 Cucchiara S, Santamaria F, Andreotti MR. , et al. Mechanisms of gastro-oesophageal reflux in cystic fibrosis. Arch Dis Child 1991; 66 (05) 617-622
- 5 Pauwels A, Blondeau K, Dupont LJ, Sifrim D. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. Am J Gastroenterol 2012; 107 (09) 1346-1353
- 6 Dimango E, Walker P, Keating C. , et al. Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulm Med 2014; 14: 21
- 7 Pauwels A, Decraene A, Blondeau K. , et al. Bile acids in sputum and increased airway inflammation in patients with cystic fibrosis. Chest 2012; 141 (06) 1568-1574
- 8 Corral JE, Dye CW, Mascarenhas MR, Barkin JS, Salathe M, Moshiree B. Is gastroparesis found more frequently in patients with cystic fibrosis? A systematic review. Scientifica (Cairo) 2016; 2016: 2918139
- 9 Hauser B, De Schepper J, Malfroot A. , et al. Gastric emptying and gastro-oesophageal reflux in children with cystic fibrosis. J Cyst Fibros 2016; 15 (04) 540-547
- 10 Kuo P, Stevens JE, Russo A. , et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011; 96 (05) E851-E855
- 11 Mertens V, Blondeau K, Pauwels A. , et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci 2009; 54 (05) 972-979
- 12 Samson C, Tamalet A, Thien HV. , et al. Long-term effects of azithromycin in patients with cystic fibrosis. Respir Med 2016; 117: 1-6
- 13 Tonelli AR, Drane WE, Collins DP, Nichols W, Antony VB, Olson EL. Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis. J Cyst Fibros 2009; 8 (03) 193-197
- 14 Sheikh SI, Ryan-Wenger NA, McCoy KS. Outcomes of surgical management of severe GERD in patients with cystic fibrosis. Pediatr Pulmonol 2013; 48 (06) 556-562
- 15 Davis Jr RD, Lau CL, Eubanks S. , et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125 (03) 533-542
- 16 Cantu III E, Appel III JZ, Hartwig MG. , et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78 (04) 1142-1151 , discussion 1142–1151
- 17 Dhaliwal J, Leach S, Katz T. , et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2015; 60 (04) 521-526
- 18 Strong TV, Boehm K, Collins FS. Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. J Clin Invest 1994; 93 (01) 347-354
- 19 De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med 2013; 3 (09) a009753
- 20 Lewindon PJ, Robb TA, Moore DJ, Davidson GP, Martin AJ. Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 1998; 34 (01) 79-82
- 21 Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 2007; 44 (02) 212-218
- 22 Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013; 38 (07) 674-688
- 23 Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the cystic fibrosis intestine. J Cyst Fibros 2017; 16 (Suppl. 02) S14-S23
- 24 Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004; 72 (10) 6040-6049
- 25 Lisowska A, Madry E, Pogorzelski A, Szydłowski J, Radzikowski A, Walkowiak J. Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis. Scand J Clin Lab Invest 2010; 70 (05) 322-326
- 26 Barbara G, Stanghellini V, Brandi G. , et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100 (11) 2560-2568
- 27 De Lisle RC. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293 (01) G104-G111
- 28 De Lisle RC, Roach E, Jansson K. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293 (03) G577-G584
- 29 Hedsund C, Gregersen T, Joensson IM, Olesen HV, Krogh K. Gastrointestinal transit times and motility in patients with cystic fibrosis. Scand J Gastroenterol 2012; 47 (8–9): 920-926
- 30 Rovner AJ, Schall JI, Mondick JT, Zhuang H, Mascarenhas MR. Delayed small bowel transit in children with cystic fibrosis and pancreatic insufficiency. J Pediatr Gastroenterol Nutr 2013; 57 (01) 81-84
- 31 Werlin SL, Benuri-Silbiger I, Kerem E. , et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010; 51 (03) 304-308
- 32 Lloyd-Still JD. Crohn's disease and cystic fibrosis. Dig Dis Sci 1994; 39 (04) 880-885
- 33 Condino AA, Hoffenberg EJ, Accurso F. , et al. Frequency of ASCA seropositivity in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 41 (01) 23-26
- 34 Van Biervliet S, Declercq D, Somerset S. Clinical effects of probiotics in cystic fibrosis patients: a systematic review. Clin Nutr ESPEN 2017; 18: 37-43
- 35 Ananthan A, Balasubramanian H, Rao S, Patole S. Probiotic supplementation in children with cystic fibrosis-a systematic review. Eur J Pediatr 2016; 175 (10) 1255-1266
- 36 Gelfond D, Heltshe S, Ma C. , et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol 2017; 8 (03) e81
- 37 Ooi CY, Syed SA, Rossi L. , et al. Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation. Sci Rep 2018; 8 (01) 17834
- 38 Sermet-Gaudelus I, De Villartay P, de Dreuzy P. , et al. Pain in children and adults with cystic fibrosis: a comparative study. J Pain Symptom Manage 2009; 38 (02) 281-290
- 39 Lusman SS, Grand R. Approach to chronic abdominal pain in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S24-S31
- 40 Fluge G, Olesen HV, Gilljam M. , et al. Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients. J Cyst Fibros 2009; 8 (03) 198-202
- 41 Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2010. Bethesda, MD: Cystic Fibrosis Foundation; 2010
- 42 Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008; 372 (9636): 415-417
- 43 Carlyle BE, Borowitz DS, Glick PL. A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. J Pediatr Surg 2012; 47 (04) 772-781
- 44 Chen EY, Yang N, Quinton PM, Chin WC. A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell Mol Physiol 2010; 299 (04) L542-L549
- 45 Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 2009; 119 (09) 2613-2622
- 46 Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol 2015; 308 (06) G459-G471
- 47 Allan JL, Robbie M, Phelan PD, Danks DM. Familial occurrence of meconium ileus. Eur J Pediatr 1981; 135 (03) 291-292
- 48 Blackman SM, Deering-Brose R, McWilliams R. , et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 2006; 131 (04) 1030-1039
- 49 Mornet E, Simon-Bouy B, Serre JL. , et al. Genetic differences between cystic fibrosis with and without meconium ileus. Lancet 1988; 1 (8582): 376-378
- 50 Dorfman R, Li W, Sun L. , et al. Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results. Hum Genet 2009; 126 (06) 763-778
- 51 Scotet V, Duguépéroux I, Audrézet MP. , et al. Focus on cystic fibrosis and other disorders evidenced in fetuses with sonographic finding of echogenic bowel: 16-year report from Brittany, France. Am J Obstet Gynecol 2010; 203 (06) 592.e1-592.e6
- 52 Ruiz MJ, Thatch KA, Fisher JC, Simpson LL, Cowles RA. Neonatal outcomes associated with intestinal abnormalities diagnosed by fetal ultrasound. J Pediatr Surg 2009; 44 (01) 71-74 , discussion 74–75
- 53 Sathe M, Houwen R. Meconium ileus in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S32-S39
- 54 Bahado-Singh R, Morotti R, Copel JA, Mahoney MJ. Hyperechoic fetal bowel: the perinatal consequences. Prenat Diagn 1994; 14 (10) 981-987
- 55 Escobar MA, Grosfeld JL, Burdick JJ. , et al. Surgical considerations in cystic fibrosis: a 32-year evaluation of outcomes. Surgery 2005; 138 (04) 560-571 , discussion 571–572
- 56 Rescorla FJ, Grosfeld JL. Contemporary management of meconium ileus. World J Surg 1993; 17 (03) 318-325
- 57 Neuhauser EB. Roentgen changes associated with pancreatic insufficiency in early life. Radiology 1946; 46: 319-328
- 58 Noblett HR. Treatment of uncomplicated meconium ileus by Gastrografin enema: a preliminary report. J Pediatr Surg 1969; 4 (02) 190-197
- 59 Mushtaq I, Wright VM, Drake DP, Mearns MB, Wood CB. Meconium ileus secondary to cystic fibrosis. The East London experience. Pediatr Surg Int 1998; 13 (5–6): 365-369
- 60 Karimi A, Gorter RR, Sleeboom C, Kneepkens CM, Heij HA. Issues in the management of simple and complex meconium ileus. Pediatr Surg Int 2011; 27 (09) 963-968
- 61 Caniano DA, Beaver BL. Meconium ileus: a fifteen-year experience with forty-two neonates. Surgery 1987; 102 (04) 699-703
- 62 Copeland DR, St Peter SD, Sharp SW. , et al. Diminishing role of contrast enema in simple meconium ileus. J Pediatr Surg 2009; 44 (11) 2130-2132
- 63 Ein SH, Shandling B, Reilly BJ, Stephens CA. Bowel perforation with nonoperative treatment of meconium ileus. J Pediatr Surg 1987; 22 (02) 146-147
- 64 Fitzgerald R, Conlon K. Use of the appendix stump in the treatment of meconium ileus. J Pediatr Surg 1989; 24 (09) 899-900
- 65 Bishop HC, Koop CE. Management of meconium ileus; resection, Roux-en-Y anastomosis and ileostomy irrigation with pancreatic enzymes. Ann Surg 1957; 145 (03) 410-414
- 66 Santulli TV, Blanc WA. Congenital atresia of the intestine: pathogenesis and treatment. Ann Surg 1961; 154: 939-948
- 67 Jawaheer J, Khalil B, Plummer T. , et al. Primary resection and anastomosis for complicated meconium ileus: a safe procedure?. Pediatr Surg Int 2007; 23 (11) 1091-1093
- 68 Del Pin CA, Czyrko C, Ziegler MM, Scanlin TF, Bishop HC. Management and survival of meconium ileus. A 30-year review. Ann Surg 1992; 215 (02) 179-185
- 69 Leeuwen L, Magoffin AK, Fitzgerald DA, Cipolli M, Gaskin KJ. Cholestasis and meconium ileus in infants with cystic fibrosis and their clinical outcomes. Arch Dis Child 2014; 99 (05) 443-447
- 70 Efrati O, Nir J, Fraser D. , et al. Meconium ileus in patients with cystic fibrosis is not a risk factor for clinical deterioration and survival: the Israeli Multicenter Study. J Pediatr Gastroenterol Nutr 2010; 50 (02) 173-178
- 71 Munck A, Gérardin M, Alberti C. , et al. Clinical outcome of cystic fibrosis presenting with or without meconium ileus: a matched cohort study. J Pediatr Surg 2006; 41 (09) 1556-1560
- 72 Houwen RH, van der Doef HP, Sermet I. , et al; ESPGHAN Cystic Fibrosis Working Group. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr 2010; 50 (01) 38-42
- 73 Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M. ; ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011; 10 (Suppl. 02) S24-S28
- 74 Dray X, Bienvenu T, Desmazes-Dufeu N, Dusser D, Marteau P, Hubert D. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol 2004; 2 (06) 498-503
- 75 Andersen HO, Hjelt K, Waever E, Overgaard K. The age-related incidence of meconium ileus equivalent in a cystic fibrosis population: the impact of high-energy intake. J Pediatr Gastroenterol Nutr 1990; 11 (03) 356-360
- 76 Munck A, Alberti C, Colombo C. , et al; CF/Pancreas ESPGHAN Working Group and DIOS Study Group. International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: associated factors and outcome. J Cyst Fibros 2016; 15 (04) 531-539
- 77 Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci 2013; 58 (08) 2275-2281
- 78 Risse PA, Kachmar L, Matusovsky OS. , et al. Ileal smooth muscle dysfunction and remodeling in cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2012; 303 (01) G1-G8
- 79 Ooi CY, Jeyaruban C, Lau J. , et al. High ambient temperature and risk of intestinal obstruction in cystic fibrosis. J Paediatr Child Health 2016; 52 (04) 430-435
- 80 Gilljam M, Chaparro C, Tullis E, Chan C, Keshavjee S, Hutcheon M. GI complications after lung transplantation in patients with cystic fibrosis. Chest 2003; 123 (01) 37-41
- 81 Morton JR, Ansari N, Glanville AR, Meagher AP, Lord RV. Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation. J Gastrointest Surg 2009; 13 (08) 1448-1453
- 82 Abraham JM, Taylor CJ. Cystic Fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros 2017; 16 (Suppl. 02) S40-S49
- 83 Pall H, Zacur GM, Kramer RE. , et al. Bowel preparation for pediatric colonoscopy: report of the NASPGHAN endoscopy and procedures committee. J Pediatr Gastroenterol Nutr 2014; 59 (03) 409-416
- 84 Zahra M, Frederick C, Thomas R, Iqbal V, Borowitz D. Gastrografin enemas for treatment of distal intestinal obstruction syndrome in children and adults with cystic fibrosis. J Pharm Nutr Sci 2014; 4 (02) 76-80
- 85 Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007; 8 (01) 24-29
- 86 Williams K, Huntington S, Shaw N, Conway SP, Peckham D. Prucalopride: a review of the first 12 months of use. J Cyst Fibros 2012; 11 (01) S115 . Available at: https://www.cysticfibrosisjournal.com/article/S1569-1993(12)60398-1/pdf . Accessed September 10, 2019
- 87 Lavie M, Manovitz T, Vilozni D. , et al. Long-term follow-up of distal intestinal obstruction syndrome in cystic fibrosis. World J Gastroenterol 2015; 21 (01) 318-325
- 88 van der Doef HP, Kokke FT, Beek FJ, Woestenenk JW, Froeling SP, Houwen RH. Constipation in pediatric cystic fibrosis patients: an underestimated medical condition. J Cyst Fibros 2010; 9 (01) 59-63
- 89 Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol 2013; 11 (04) 333-342 , quiz e30–e31
- 90 Sinaasappel M, Stern M, Littlewood J. , et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2002; 1 (02) 51-75
- 91 Assis DN, Freedman SD. Gastrointestinal disorders in cystic fibrosis. Clin Chest Med 2016; 37 (01) 109-118
- 92 Tabbers MM, DiLorenzo C, Berger MY. , et al; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; North American Society for Pediatric Gastroenterology. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58 (02) 258-274
- 93 Clark JH, Russell GJ, Fitzgerald JF, Nagamori KE. Serum beta-carotene, retinol, and alpha-tocopherol levels during mineral oil therapy for constipation. Am J Dis Child 1987; 141 (11) 1210-1212
- 94 Sharif F, Crushell E, O'Driscoll K, Bourke B. Liquid paraffin: a reappraisal of its role in the treatment of constipation. Arch Dis Child 2001; 85 (02) 121-124
- 95 Camilleri M, Piessevaux H, Yiannakou Y. , et al. Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci 2016; 61 (08) 2357-2372
- 96 O'Brien CE, Anderson PJ, Stowe CD. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study. Ann Pharmacother 2011; 45 (09) 1061-1066
- 97 McHugh DR, Cotton CU, Moss FJ. , et al. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am J Physiol Gastrointest Liver Physiol 2018; 315 (05) G868-G878
- 98 Holsclaw DS, Rocmans C, Shwachman H. Intussusception in patients with cystic fibrosis. Pediatrics 1971; 48 (01) 51-58
- 99 Hafen GM, Taylor AC, Oliver MR. , et al. Intussusceptions arising from two different sites in a child with cystic fibrosis. Pediatr Pulmonol 2005; 40 (04) 358-361
- 100 Beck AR, Aterman K. Intestinal obstruction and mucoviscidosis. Gastroenterologia 1966; 106 (02) 86-96
- 101 Chaun H. Colonic disorders in adult cystic fibrosis. Can J Gastroenterol 2001; 15 (09) 586-590
- 102 Agrons GA, Corse WR, Markowitz RI, Suarez ES, Perry DR. Gastrointestinal manifestations of cystic fibrosis: radiologic-pathologic correlation. Radiographics 1996; 16 (04) 871-893
- 103 Lavelle LP, McEvoy SH, Ni Mhurchu E. , et al. Cystic fibrosis below the diaphragm: abdominal findings in adult patients. Radiographics 2015; 35 (03) 680-695
- 104 Timothy Adewale A, Rowe SM, Solomon GM. Colocolonic intussusception in an adult cystic fibrosis patient. J Cyst Fibros 2019; 18 (02) e11-e13
- 105 Coughlin JP, Gauderer MW, Stern RC, Doershuk CF, Izant Jr RJ, Zollinger Jr RM. The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg 1990; 25 (08) 835-839
- 106 Lardenoye SW, Puylaert JB, Smit MJ, Holscher HC. Appendix in children with cystic fibrosis: US features. Radiology 2004; 232 (01) 187-189
- 107 Keyzer C, Knoop C, Van Wettere M. , et al. Cystic fibrosis: unenhanced CT description of the appendix in asymptomatic adults. AJR Am J Roentgenol 2014; 202 (04) 759-764
- 108 McCarthy VP, Mischler EH, Hubbard VS, Chernick MS, di Sant'Agnese PA. Appendiceal abscess in cystic fibrosis. A diagnostic challenge. Gastroenterology 1984; 86 (03) 564-568
- 109 Shields MD, Levison H, Reisman JJ, Durie PR, Canny GJ. Appendicitis in cystic fibrosis. Arch Dis Child 1991; 66 (03) 307-310
- 110 Bauer MP, Farid A, Bakker M, Hoek RA, Kuijper EJ, van Dissel JT. Patients with cystic fibrosis have a high carriage rate of non-toxigenic Clostridium difficile. Clin Microbiol Infect 2014; 20 (07) O446-O449
- 111 Freedman SD, Uppot RN, Mino-Kenudson M. Case records of the Massachusetts General Hospital. Case 26-2009. A 34-year-old man with cystic fibrosis with abdominal pain and distention. N Engl J Med 2009; 361 (08) 807-816
- 112 Piccolo F, Tai AS, Ee H, Mulrennan S, Bell S, Ryan G. Clostridium difficile infection in cystic fibrosis: an uncommon but life-threatening complication. Respirol Case Rep 2016; 5 (01) e00204
- 113 McDonald LC, Gerding DN, Johnson S. , et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society Of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66 (07) 987-994
- 114 Smyth RL, van Velzen D, Smyth AR, Lloyd DA, Heaf DP. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343 (8889): 85-86
- 115 FitzSimmons SC, Burkhart GA, Borowitz D. , et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336 (18) 1283-1289
- 116 Freiman JP, FitzSimmons SC. Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centers in the United States. J Pediatr Gastroenterol Nutr 1996; 22 (02) 153-156
- 117 Schwarzenberg SJ, Wielinski CL, Shamieh I. , et al. Cystic fibrosis-associated colitis and fibrosing colonopathy. J Pediatr 1995; 127 (04) 565-570
- 118 Lloyd-Still JD. Cystic fibrosis and colonic strictures. A new “iatrogenic” disease. J Clin Gastroenterol 1995; 21 (01) 2-5
- 119 Serban DE, Florescu P, Miu N. Fibrosing colonopathy revealing cystic fibrosis in a neonate before any pancreatic enzyme supplementation. J Pediatr Gastroenterol Nutr 2002; 35 (03) 356-359
- 120 Demeyer S, De Boeck K, Witters P, Cosaert K. Beyond pancreatic insufficiency and liver disease in cystic fibrosis. Eur J Pediatr 2016; 175 (07) 881-894
- 121 Almberger M, Iannicelli E, Antonelli M, Matrunola M, Cimino G, Passariello R. The role of MRI in the intestinal complications in cystic fibrosis. Clin Imaging 2001; 25 (05) 344-348
- 122 Terheggen G, Dieninghoff D, Rietschel E, Drebber U, Kruis W, Leifeld L. Successful non-invasive treatment of stricturing fibrosing colonopathy in an adult patient. Eur J Med Res 2011; 16 (09) 411-414
- 123 Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105 (02) 122-129
- 124 Neglia JP, FitzSimmons SC, Maisonneuve P. , et al; Cystic Fibrosis and Cancer Study Group. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study group. N Engl J Med 1995; 332 (08) 494-499
- 125 Corriveau S, Sykes J, Stephenson AL. Cystic fibrosis survival: the changing epidemiology. Curr Opin Pulm Med 2018; 24 (06) 574-578
- 126 Kushi LH, Doyle C, McCullough M. , et al; American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012; 62 (01) 30-67
- 127 Ren X, Zhang X, Zhang X. , et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health 2009; 123 (08) 540-544
- 128 Fink AK, Yanik EL, Marshall BC. , et al. Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros 2017; 16 (01) 91-97
- 129 Mima K, Ogino S, Nakagawa S. , et al. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg Oncol 2017; 26 (04) 368-376
- 130 Arthur JC, Perez-Chanona E, Mühlbauer M. , et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 338 (6103): 120-123
- 131 Than BL, Linnekamp JF, Starr TK. , et al. CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 2016; 35 (32) 4179-4187
- 132 Niccum DE, Billings JL, Dunitz JM, Khoruts A. Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis. J Cyst Fibros 2016; 15 (04) 548-553
- 133 Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB. ; Cystic Fibrosis Colorectal Cancer Screening Task Force. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology 2018; 154 (03) 736-745.e14
- 134 Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105 (06) 1857-1864
- 135 Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004; 6 (03) 231-239
- 136 Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. J Cyst Fibros 2017; 16 (Suppl. 02) S50-S61
- 137 Hillaire S, Cazals-Hatem D, Bruno O. , et al. Liver transplantation in adult cystic fibrosis: clinical, imaging, and pathological evidence of obliterative portal venopathy. Liver Transpl 2017; 23 (10) 1342-1347
- 138 Witters P, Libbrecht L, Roskams T. , et al. Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. J Cyst Fibros 2017; 16 (05) e11-e13
- 139 Wu H, Vu M, Dhingra S. , et al. Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension. Clin Gastroenterol Hepatol 2018; 17 (10) 2134-2136
- 140 Debray D, Narkewicz MR, Bodewes FAJA. , et al. Cystic fibrosis-related liver disease: research challenges and future perspectives. J Pediatr Gastroenterol Nutr 2017; 65 (04) 443-448
- 141 Stonebraker JR, Ooi CY, Pace RG. , et al. Features of severe liver disease with portal hypertension in patients with cystic fibrosis. Clin Gastroenterol Hepatol 2016; 14 (08) 1207.e3-1215.e3
- 142 Colombo C, Battezzati PM, Crosignani A. , et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36 (06) 1374-1382
- 143 Koh C, Sakiani S, Surana P. , et al. Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity. Hepatology 2017; 66 (02) 591-601
- 144 Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011; 10 (Suppl. 02) S29-S36
- 145 Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30 (05) 1151-1158
- 146 Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004; 41 (06) 920-925
- 147 Efrati O, Barak A, Modan-Moses D. , et al. Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003; 15 (10) 1073-1078
- 148 Bartlett JR, Friedman KJ, Ling SC. , et al; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302 (10) 1076-1083
- 149 Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007; 13 (06) 529-536
- 150 Lewindon PJ, Puertolas-Lopez MV, Ramm LE. , et al. Accuracy of transient elastography data combined with APRI in detection and staging of liver disease in pediatric patients with cystic fibrosis. Clin Gastroenterol Hepatol 2019 ;(e-pub ahead of print). Doi: 10.1016/j.cgh.2019.03.015
- 151 Boëlle PY, Debray D, Guillot L, Clement A, Corvol H, French CF. ; French CF Modifier Gene Study Investigators. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology 2019; 69 (04) 1648-1656
- 152 Borowitz D, Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 2013; 19 (06) 676-680
- 153 Fawaz R, Baumann U, Ekong U. , et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64 (01) 154-168
- 154 Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996; 75 (01) 67-70
- 155 Shapira R, Hadzic N, Francavilla R, Koukulis G, Price JF, Mieli-Vergani G. Retrospective review of cystic fibrosis presenting as infantile liver disease. Arch Dis Child 1999; 81 (02) 125-128
- 156 Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975; 86 (05) 683-689
- 157 Perkins WG, Klein GL, Beckerman RC. Cystic fibrosis mistaken for idiopathic biliary atresia. Clin Pediatr (Phila) 1985; 24 (02) 107-109
- 158 Greenholz SK, Krishnadasan B, Marr C, Cannon R. Biliary obstruction in infants with cystic fibrosis requiring Kasai portoenterostomy. J Pediatr Surg 1997; 32 (02) 175-179 , discussion 179–180
- 159 Lewindon PJ, Shepherd RW, Walsh MJ. , et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53 (01) 193-201
- 160 Treem WR, Stanley CA. Massive hepatomegaly, steatosis, and secondary plasma carnitine deficiency in an infant with cystic fibrosis. Pediatrics 1989; 83 (06) 993-997
- 161 Chen AH, Innis SM, Davidson AG, James SJ. Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. Am J Clin Nutr 2005; 81 (03) 686-691
- 162 Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros 2013; 12 (02) 116-124
- 163 Patriquin H, Lenaerts C, Smith L. , et al. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. Radiology 1999; 211 (01) 229-232
- 164 Angelico M, Gandin C, Canuzzi P. , et al. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology 1991; 14 (05) 768-775
- 165 Colombo C, Bertolini E, Assaisso ML, Bettinardi N, Giunta A, Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993; 82 (6–7): 562-565
- 166 Vítek L, Carey MC. New pathophysiological concepts underlying pathogenesis of pigment gallstones. Clin Res Hepatol Gastroenterol 2012; 36 (02) 122-129
- 167 Kuver R, Lee SP. Calcium binding to biliary mucins is dependent on sodium ion concentration: relevance to cystic fibrosis. Biochem Biophys Res Commun 2004; 314 (02) 330-334
- 168 Akata D, Akhan O. Liver manifestations of cystic fibrosis. Eur J Radiol 2007; 61 (01) 11-17
- 169 Assis DN, Debray D. Gallbladder and bile duct disease in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S62-S69
- 170 Beuers U, Maroni L, Elferink RO. The biliary HCO(3)(-) umbrella: experimental evidence revisited. Curr Opin Gastroenterol 2012; 28 (03) 253-257
- 171 Fiorotto R, Scirpo R, Trauner M. , et al. Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice. Gastroenterology 2011; 141 (04) 1498-1508 , 1508.e1–1508.e5
- 172 Durieu I, Pellet O, Simonot L. , et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999; 30 (06) 1052-1056
- 173 Buxbaum J, Nguyen N, Kulkarni S, Palmer S, Rao A, Selby R. Multidisciplinary treatment of cystic fibrosis-related recurrent pyogenic cholangitis (CF-RPC). Dig Dis Sci 2015; 60 (06) 1801-1804
- 174 Perdue DG, Cass OW, Milla C. , et al. Hepatolithiasis and cholangiocarcinoma in cystic fibrosis: a case series and review of the literature. Dig Dis Sci 2007; 52 (10) 2638-2642
- 175 Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2017; 9: CD000222
- 176 Mon Martín F, Martín Malagón AI, Arteaga González IJ, Díaz Luís H, Carrillo Pallares AL. Hepatolithiasis in cystic fibrosis: a special condition for surgical treatment. Cir Esp 2014; 92 (09) 634-635
- 177 Wilschanski M, Durie PR. Pathology of pancreatic and intestinal disorders in cystic fibrosis. J R Soc Med 1998; 91 (Suppl. 34) 40-49
- 178 Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S70-S78
- 179 Borowitz D, Robinson KA, Rosenfeld M. , et al; Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155 (6, Suppl): S73-S93
- 180 Borowitz D, Baker SS, Duffy L. , et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004; 145 (03) 322-326
- 181 Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy 2007; 27 (06) 910-920
- 182 Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr 2003; 162 (11) 760-763
- 183 Turck D, Braegger CP, Colombo C. , et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35 (03) 557-577
- 184 Rosenfeld M, Wainwright CE, Higgins M. , et al; ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med 2018; 6 (07) 545-553
- 185 Maqbool A, Pauwels A. Cystic Fibrosis and gastroesophageal reflux disease. J Cyst Fibros 2017; 16 (Suppl. 02) S2-S13